Subject(s)
Genetic Therapy/methods , Hematopoietic Stem Cell Transplantation/methods , Leukodystrophy, Metachromatic/drug therapy , Leukodystrophy, Metachromatic/therapy , Platelet Aggregation Inhibitors/therapeutic use , Polydeoxyribonucleotides/therapeutic use , Transplantation Conditioning/methods , Humans , Leukodystrophy, Metachromatic/pathology , Male , Platelet Aggregation Inhibitors/pharmacology , Polydeoxyribonucleotides/pharmacology , TwinsABSTRACT
Human ciliopathies are hereditary conditions caused by defects of proteins expressed at the primary cilium. Among ciliopathies, Joubert syndrome and related disorders (JSRD), Meckel syndrome (MKS) and nephronophthisis (NPH) present clinical and genetic overlap, being allelic at several loci. One of the most interesting gene is TMEM67, encoding the transmembrane protein meckelin. We performed mutation analysis of TMEM67 in 341 probands, including 265 JSRD representative of all clinical subgroups and 76 MKS fetuses. We identified 33 distinct mutations, of which 20 were novel, in 8/10 (80%) JS with liver involvement (COACH phenotype) and 12/76 (16%) MKS fetuses. No mutations were found in other JSRD subtypes, confirming the strong association between TMEM67 mutations and liver involvement. Literature review of all published TMEM67 mutated cases was performed to delineate genotype-phenotype correlates. In particular, comparison of the types of mutations and their distribution along the gene in lethal versus non lethal phenotypes showed in MKS patients a significant enrichment of missense mutations falling in TMEM67 exons 8 to 15, especially when in combination with a truncating mutation. These exons encode for a region of unknown function in the extracellular domain of meckelin.
